This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Telatinib
- DrugBank Accession Number
- DB15393
- Background
Telatinib is under investigation in clinical trial NCT03817411 (Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Telatinib (DB15393)
- Weight
- Average: 409.83
Monoisotopic: 409.0941671 - Chemical Formula
- C20H16ClN5O3
- Synonyms
- Telatinib
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyridinecarboxamides. These are compounds containing a pyridine ring bearing a carboxamide.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Pyridinecarboxylic acids and derivatives
- Direct Parent
- Pyridinecarboxamides
- Alternative Parents
- 2-heteroaryl carboxamides / Aniline and substituted anilines / Alkyl aryl ethers / Aminopyridazines / Chlorobenzenes / Imidolactams / Aryl chlorides / Heteroaromatic compounds / Furans / Secondary carboxylic acid amides show 6 more
- Substituents
- 2-heteroaryl carboxamide / Alkyl aryl ether / Amine / Aminopyridazine / Aniline or substituted anilines / Aromatic heteropolycyclic compound / Aryl chloride / Aryl halide / Azacycle / Benzenoid show 21 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 18P7197Q7J
- CAS number
- 332012-40-5
- InChI Key
- QFCXANHHBCGMAS-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25)
- IUPAC Name
- 4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methylpyridine-2-carboxamide
- SMILES
- CNC(=O)C1=CC(COC2=C3OC=CC3=C(NC3=CC=C(Cl)C=C3)N=N2)=CC=N1
References
- General References
- Not Available
- External Links
- ChemSpider
- 7984603
- BindingDB
- 50399538
- ChEMBL
- CHEMBL2079588
- ZINC
- ZINC000000590964
- PharmGKB
- PA165980595
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Active Not Recruiting Treatment Gastric Cancer / Hepatocellular Carcinoma 1 2 Completed Treatment Gastric Cancer 1 2 Unknown Status Treatment Gastric Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0615 mg/mL ALOGPS logP 3.79 ALOGPS logP 2.98 Chemaxon logS -3.8 ALOGPS pKa (Strongest Acidic) 14.28 Chemaxon pKa (Strongest Basic) 2.05 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 102.17 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 109.05 m3·mol-1 Chemaxon Polarizability 41.65 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at May 20, 2019 15:24 / Updated at February 21, 2021 18:55